Hydrocortisone Activase Pharmaceuticals

Hydrocortisone Activase Pharmaceuticals is an oral medication that contains the corticosteroid hydrocortisone as its active ingredient. Marketed in the European Union, this product is supplied in tablet form (strength not specified) and is classified as an anti‑inflammatory agent. It works by binding to glucocorticoid receptors to modulate immune responses and reduce inflammation, making it suitable for various endocrine, clinical, and inflammatory conditions, including adrenal insufficiency and hypotension.

Hydrocortisone Activase Pharmaceuticals is used orally for conditions where glucocorticoid replacement or anti‑inflammatory effects are required.

- Replacement therapy in primary or secondary adrenal insufficiency to maintain normal cortisol levels. - Management of acute inflammatory episodes such as severe allergic reactions, including angioedema and anaphylaxis. - Treatment of chronic inflammatory disorders like rheumatoid arthritis or systemic lupus erythematosus when other therapies are insufficient or contraindicated. - Adjunct therapy for certain dermatologic conditions that respond to systemic steroids, such as severe psoriasis or eczema. - Supportive care in shock, severe stress, or postoperative periods where endogenous cortisol production may be inadequate.

Oral hydrocortisone may cause a range of adverse reactions, which are generally classified by frequency and severity, and should be monitored by healthcare professionals.

Common: - Increased appetite or mild weight gain, often noticeable after several weeks of therapy. - Fluid retention causing mild peripheral edema, especially in the lower extremities. - Elevated blood glucose levels, which may require monitoring in diabetic patients. - Mood changes such as irritability, anxiety, or difficulty sleeping.

Serious: - Severe allergic reaction (anaphylaxis) presenting with widespread rash, facial swelling, or difficulty breathing, requiring immediate medical attention. - Signs of infection, such as fever or persistent cough, and worsening hypertension due to fluid overload or vascular effects.

When prescribing or taking Hydrocortisone Activase Pharmaceuticals, several precautionary measures should be considered to minimize risks and ensure safe use.

- Assess adrenal function before initiating therapy and monitor cortisol levels during treatment. - Use the lowest effective dose for the shortest duration necessary to control symptoms. - Caution in patients with diabetes, hypertension, or a history of cardiovascular disease. - Evaluate for existing infections; hydrocortisone may mask typical signs of infection. - Avoid abrupt discontinuation to prevent adrenal crisis; tapering is recommended under medical supervision. - Discuss potential effects on bone density with long‑term use and consider supplementation or monitoring.

Hydrocortisone can influence the activity of several other medicines; awareness of these interactions helps prevent reduced efficacy or increased toxicity.

Avoid: - Concurrent use with potent CYP3A4 inducers such as rifampin, which may markedly lower hydrocortisone plasma concentrations. - Co‑administration with strong CYP3A4 inhibitors like ketoconazole, which can increase systemic exposure and risk of side effects.

Use with caution: - Non‑steroidal anti‑inflammatory drugs (NSAIDs) may increase the risk of gastrointestinal ulceration or bleeding. - Anticoagulants, e.g., warfarin, may have enhanced anticoagulant effects, requiring closer INR monitoring. - Vaccines, especially live attenuated vaccines, may have reduced efficacy or increased risk of infection. - Diabetic medications may require dose adjustment due to hydrocortisone‑induced hyperglycemia.